Mallinckrodt Looks To Increase Hospital Product Offerings With Questcor Purchase
This article was originally published in The Pink Sheet Daily
Executive Summary
Less than a year after its spinout, Mallinckrodt has announced its second large acquisition, paying $5.6 billion for Questcor and its potential blockbuster product.
You may also be interested in...
Why Is Congress Targeting These Six Medicines In Drug Price Hearing?
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
The ‘Re-Pricer’ Reckoning: Makena, Daraprim And Acthar Under Pressure
The controversies have shown that, while it may be easy to scapegoat outliers, it is remarkably hard to lower a drug price by political fiat. It took a while, but now Makena, Daraprim and Acthar are all facing very different days of reckoning.
Payer Pushback Underpins Mallinckrodt's Disappointing Q3 Results
Mallinckrodt's high-priced H.P Acthar Gel was under pressure in the third quarter, which management attributed to payer complexities. The issue is broader than just Acthar, firm says.